In addition, the percentages of PD1+ CD4 T and CD8 T cells, a population reported to contain tumor-reactive lymphocytes [10], were greatly increased after the T-VEC plus anti-PD1 based therapy in all complete responders but not in partial responders (Fig. 6c). Here, CD4 is linked to neoplasm.